Author

Laura Ruiz-Cañas

COMBINATION THERAPY FOR THE TREATMENT OF KRAS-MUTANT PANCREATIC CANCER: PRE-CLINICAL INVESTIGATION OF THE NOVEL INHIBITORS RMC-4550 (SHP2I) AND LY3214996 (ERKI)
COMBINATION THERAPY FOR THE TREATMENT OF KRAS-MUTANT PANCREATIC CANCER: PRE-CLINICAL INVESTIGATION OF THE NOVEL INHIBITORS RMC-4550 (SHP2I) AND LY3214996 (ERKI)

Laura Ruiz-Cañas  et al.

CONTEXT-SPECIFIC TUMOR-SUPPRESSOR AND ONCOGENIC ACTIVITY OF NF-ΚB TRANSCRIPTION FACTOR C-REL IN PANCREATIC CANCER: NAVIGATING COMPLEXITY AND INSIGHTS INTO TUMOR BIOLOGY
CONTEXT-SPECIFIC TUMOR-SUPPRESSOR AND ONCOGENIC ACTIVITY OF NF-ΚB TRANSCRIPTION FACTOR C-REL IN PANCREATIC CANCER: NAVIGATING COMPLEXITY AND INSIGHTS INTO TUMOR BIOLOGY

Laura Ruiz-Cañas  et al.

Item 1 - 2 / 2
1